Anamorelin (ONO-7643) for the treatment of patients with non-small cell lung cancer and cachexia: Results from a randomized, double-blind, placebo-controlled, multicenter study of Japanese patients (ONO-7643-04).

MLA

Katakami, Nobuyuki, et al. “Anamorelin (ONO-7643) for the Treatment of Patients with Non-Small Cell Lung Cancer and Cachexia: Results from a Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Japanese Patients (ONO-7643-04).” Cancer (0008543X), vol. 124, no. 3, Feb. 2018, pp. 606–16. EBSCOhost, https://doi.org/10.1002/cncr.31128.

APA

Katakami, N., Uchino, J., Yokoyama, T., Naito, T., Kondo, M., Yamada, K., Kitajima, H., Yoshimori, K., Sato, K., Saito, H., Aoe, K., Tsuji, T., Takiguchi, Y., Takayama, K., Komura, N., Takiguchi, T., & Eguchi, K. (2018). Anamorelin (ONO-7643) for the treatment of patients with non-small cell lung cancer and cachexia: Results from a randomized, double-blind, placebo-controlled, multicenter study of Japanese patients (ONO-7643-04). Cancer (0008543X), 124(3), 606–616. https://doi.org/10.1002/cncr.31128

Chicago

Katakami, Nobuyuki, Junji Uchino, Takuma Yokoyama, Tateaki Naito, Masashi Kondo, Kouzo Yamada, Hiromoto Kitajima, et al. 2018. “Anamorelin (ONO-7643) for the Treatment of Patients with Non-Small Cell Lung Cancer and Cachexia: Results from a Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Japanese Patients (ONO-7643-04).” Cancer (0008543X) 124 (3): 606–16. doi:10.1002/cncr.31128.